3-Factor versus 4-Factor Prothrombin Complex Concentrates for the Reversal of Vitamin K Antagonist-Associated Coagulopathy: A Systematic Review and Meta-analysis.
Humans
Vitamin K
Blood Coagulation Factors
/ therapeutic use
Anticoagulants
/ adverse effects
Blood Coagulation Disorders
/ chemically induced
Hemorrhage
/ chemically induced
Factor IX
/ adverse effects
Thromboembolism
/ prevention & control
Fibrinolytic Agents
International Normalized Ratio
Retrospective Studies
Journal
Thrombosis and haemostasis
ISSN: 2567-689X
Titre abrégé: Thromb Haemost
Pays: Germany
ID NLM: 7608063
Informations de publication
Date de publication:
Jan 2023
Jan 2023
Historique:
entrez:
10
1
2023
pubmed:
11
1
2023
medline:
13
1
2023
Statut:
ppublish
Résumé
Long-term anticoagulation is used worldwide to prevent or treat thrombotic events. Anticoagulant therapy using vitamin K antagonists (VKAs) is well established; however, anticoagulants carry an increased risk of potentially life-threatening bleeding. In cases of bleeding or need for surgery, patients require careful management, balancing the need for rapid anticoagulant reversal with risk of thromboembolic events. Prothrombin complex concentrates (PCCs) replenish clotting factors and reverse VKA-associated coagulopathy. Two forms of PCC, 3-factor (3F-PCC) and 4-factor (4F-PCC), are available. Using PRISMA methodology, we systematically reviewed whether 4F-PCC is superior to 3F-PCC for the reversal of VKA-associated coagulopathy. Of the 392 articles identified, 48 full texts were reviewed, with 11 articles identified using criteria based on the PICOS format. Data were captured from 1,155 patients: 3F-PCC,
Identifiants
pubmed: 36626899
doi: 10.1055/s-0042-1758653
pmc: PMC9928532
doi:
Substances chimiques
prothrombin complex concentrates
37224-63-8
Vitamin K
12001-79-5
Blood Coagulation Factors
0
Anticoagulants
0
Factor IX
9001-28-9
Fibrinolytic Agents
0
Types de publication
Meta-Analysis
Systematic Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
40-53Informations de copyright
Thieme. All rights reserved.
Déclaration de conflit d'intérêts
O.G. has received research funding from Alexion, Bayer, Biotest, Boehringer Ingelheim, CSL Behring, Octapharma, Novo Nordisk, Nycomed, and Werfen. He has also received honoraria for lectures and consultancy support from Baxalta, Bayer AG, Boehringer Ingelheim, Ferring, CSL Behring, Octapharma, Pfizer, Takeda, Portola, and Sanofi. H.S. has received speaker fees from CSL Behring, TEM International, Haemonetics, and Stago.
Références
Neurocrit Care. 2016 Feb;24(1):6-46
pubmed: 26714677
Ann Intern Med. 2003 Dec 2;139(11):893-900
pubmed: 14644891
Am J Emerg Med. 2017 Jun;35(6):871-874
pubmed: 28161220
BMC Med Res Methodol. 2005 Apr 20;5:13
pubmed: 15840177
J Pharm Pract. 2018 Jun;31(3):262-267
pubmed: 28468525
Int J Crit Illn Inj Sci. 2018 Jan-Mar;8(1):36-40
pubmed: 29619338
Cochrane Database Syst Rev. 2019 Oct 3;10:ED000142
pubmed: 31643080
Anesth Analg. 2016 May;122(5):1287-300
pubmed: 26983050
Semin Thromb Hemost. 2020 Feb;46(1):32-37
pubmed: 31537028
BMC Emerg Med. 2020 Nov 26;20(1):93
pubmed: 33243152
Neurol Sci. 2019 Apr;40(4):813-827
pubmed: 30689075
Blood. 2014 Sep 18;124(12):1968-75
pubmed: 24963045
Thromb Res. 2012 Dec;130(6):833-40
pubmed: 23137921
Stroke. 2011 Jan;42(1):112-8
pubmed: 21148442
Circulation. 2013 Sep 10;128(11):1234-43
pubmed: 23935011
Stat Med. 2002 Jun 15;21(11):1539-58
pubmed: 12111919
Am J Ther. 2018 May/Jun;25(3):e326-e332
pubmed: 28763307
Thromb J. 2003 Nov 30;1(1):7
pubmed: 14969588
Blood Coagul Fibrinolysis. 1997 Jan;8(1):48-53
pubmed: 9105637
J Emerg Med. 2016 Jan;50(1):7-13
pubmed: 26433428
Circulation. 2007 May 29;115(21):2689-96
pubmed: 17515465
Clin Chem. 2005 Mar;51(3):553-60
pubmed: 15665046
Neurocrit Care. 2018 Feb;28(1):43-50
pubmed: 28612131
BMC Med Res Methodol. 2014 Dec 19;14:135
pubmed: 25524443
Lancet. 2015 May 23;385(9982):2077-87
pubmed: 25728933
Blood Adv. 2018 Nov 27;2(22):3257-3291
pubmed: 30482765
Heart Lung Circ. 2019 Nov;28(11):1706-1713
pubmed: 30309711
World J Emerg Surg. 2014 Apr 15;9:27
pubmed: 24731393
J Thromb Thrombolysis. 2016 Jul;42(1):19-26
pubmed: 26721625
Int J Lab Hematol. 2021 Feb;43(1):21-28
pubmed: 32979036
BMJ. 2016 Oct 12;355:i4919
pubmed: 27733354
Chest. 2008 Jun;133(6 Suppl):257S-298S
pubmed: 18574268
J Thromb Thrombolysis. 2017 Jul;44(1):118-129
pubmed: 28540468
J Crit Care. 2016 Jun;33:252-6
pubmed: 27021851
Thromb Res. 2015 Sep;136(3):595-8
pubmed: 26233569
Thromb Haemost. 2016 Oct 28;116(5):879-890
pubmed: 27488143
Ann Thorac Surg. 2019 May;107(5):1409-1415
pubmed: 30476474
Int J Surg. 2021 Apr;88:105906
pubmed: 33789826
Expert Opin Pharmacother. 2016 Nov;17(16):2149-2164
pubmed: 27685458
Am J Hematol. 1998 Mar;57(3):193-9
pubmed: 9495368